Background-In contrast to whites, black smokers prefer menthol cigarettes over nonmenthol cigarettes by a large margin and tend to have higher mortality from several smoking-related diseases than whites, raising the possibility that menthol cigarettes contribute to racial disparities in risk. Evidence for differential associations between menthol and nonmenthol cigarettes indicates lower cancer risk for menthol smokers, but for cardiovascular disease (CVD) mortality, evidence has been inconsistent. Methods and Results-Cox proportional hazards models were used to compute hazard ratios and accompanying 95% confidence intervals for all-cause and CVD mortality for menthol compared with nonmenthol cigarette smokers among 65 600 participants in the Southern Community Cohort Study, an ongoing community-based cohort with the largest number of menthol smokers being traced. Among the 27 619 current cigarette smokers, 4224 died during follow-up, with 1130 deaths attributed to CVD. Both all-cause (hazard ratio=0.93; 95% confidence interval=0.86-1.01; P=0.10) and CVD (hazard ratio=0.88; 95% confidence interval=0.76-1.03; P=0.10) mortality risks were similar in menthol compared with nonmenthol cigarette smokers. Conclusions-Smoking regardless of cigarette type is hazardous to health, but these results do not indicate that menthol cigarettes are associated with greater CVD risks than nonmenthol cigarettes.
M
enthol is a chemical compound with mild local anesthetic qualities and a mint scent that is added to some cigarettes. Smokers have reported that they experienced easier and deeper inhalation and less irritation in the throat while smoking menthol cigarettes. 1 It has been suggested that mentholation may affect cigarette smoking behaviors such as initiation, inhalation, dependency, and cessation. 2 Menthol cigarette smoking is much more prevalent among black smokers than white smokers, and in recent years (2004) (2005) (2006) (2007) (2008) (2009) (2010) , menthol cigarette use has remained stable in adults while nonmenthol cigarette use has declined. 3, 4 Blacks experience a higher incidence of and mortality from several smoking-related diseases, including cardiovascular disease (CVD) and stroke, 5 but whether menthol cigarette smoking contributes to these differentials is not clear, with inconsistent evidence from the few studies [6] [7] [8] that have examined risks of these illnesses in menthol versus nonmenthol smokers. The issue is topical because the US Food and Drug Administration has been deliberating the regulation of menthol cigarettes since the Tobacco Control Act, a law banning the use of all flavoring except menthol in cigarettes, was passed in 2009. The Southern Community Cohort Study (SCCS), with its large number of black smokers, affords the unique opportunity to assess the effects of menthol cigarette use on smoking-related mortality.
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Methods
Study Design and Participants
The SCCS is an ongoing, prospective cohort study designed to investigate health disparities between blacks and whites in underserved populations in the following 12 southeastern states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia. 9, 10 More than 85 000 adults, two-thirds black, between 40 and 79 years of age were enrolled from 2002 to 2009 either in person at 1 of 71 community health centers (≈85%) or by mailings to stratified random samples of the general populations of these states. Participants completed a questionnaire via personal interview at community health centers with detailed information on demographic, socioeconomic, and anthropometric characteristics; personal and family medical histories; and lifestyle choices such as tobacco and alcohol use and diet. Vital status was ascertained through direct contact with participants and linkages with the National Death Index and the Social Security Administration's Service for Epidemiological Research. For analyses of all-cause mortality and cause-specific mortality, follow-up ended at the date of death, date lost to follow-up, or December 31, 2013 (the
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May 10, 2016 latest date for which cause of death was available from the National Death Index). The study was approved by the institutional review boards of Vanderbilt University and Meharry Medical College, and participants gave written informed consent at study enrollment. Participants were asked whether they had smoked at least 100 cigarettes in their entire lifetime and, if they had, whether they still smoked at the time of enrollment in the study. They were also asked the average number of cigarettes they smoke (or used to smoke) in 1 day and whether the cigarettes were usually menthol. Our primary variable of interest, smoking status at cohort entry, was defined as never smoker (reference), former smoker of menthol cigarettes, former smoker of nonmenthol cigarettes, current smoker of <10 menthol cigarettes per day, current smoker of <10 nonmenthol cigarettes per day, current smoker of 10 to 19 menthol cigarettes per day, current smoker of 10 to 19 nonmenthol cigarettes per day, current smoker of ≥20 menthol cigarettes per day, and current smoker of ≥20 nonmenthol cigarettes per day. Data on age at enrollment, age of smoking initiation, and age at cessation (for former smokers) were available to calculate smoking duration. Pack-years of smoking were calculated by dividing the number of cigarettes smoked per day by 20 to determine the number of packs per day and then multiplying by smoking duration in years.
Of the initial 84 563 active participants, those who reported a race other than black or white (n=4126), had data determined to be unreliable (n=804), reported having had cancer other than nonmelanoma skin cancer or a history of myocardial infarction or coronary artery bypass surgery at baseline (n=11 248), were missing information on the covariates included in the models (n=2592), were missing cause of death for those who died (n=177), or had the same age in months at enrollment and at the end of follow-up resulting in 0 months of follow-up time (n=16) were excluded from the cohort, resulting in 65 600 participants available for the analyses. Individuals reporting chronic obstructive pulmonary disease were also excluded in sensitivity analyses, but they were retained in the final models because the exclusion resulted in little differences in the risk estimates.
Statistical Analysis
Pearson χ 2 , ANOVA, and Kruskal-Wallis tests were performed to assess differences between race, sex, or race-sex groups for variables included in the analyses. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality from all causes of death (n=7689) and deaths with CVD (n=2289; International Classification of Diseases, 10th Revision [ICD-10] codes I00-I78), heart disease (n=1687; ICD-10 codes I00-I09, I11, I13, I20-I51), and stroke (n=389; ICD-10 codes I60-I69) as the underlying cause among SCCS participants after enrollment in the cohort. In addition, for comparative purposes, we computed HRs for cancer (n=1875; ICD-10 codes C00-C97), lung cancer (n=649; ICD-10 code C34), all types of cancer except lung cancer (n=1226; ICD-10 codes C00-C33, C35-C97), and nonasthma chronic obstructive pulmonary disease (n=313; ICD-10 codes J40-J44, J47). Age in months was used as the time scale for all models starting at age of enrollment and ending at age of death, age of loss to follow-up, or age as of December 31, 2013, whichever came first. HRs associated with the 8 categories of smokers relative to never smokers were computed for each of the causes of death. We then analyzed the effects of mentholation (yes versus no) among current cigarette smokers, adjusting for pack-years (continuous).
The following covariates were included in all models: race (black versus white), sex (female versus male), education (did not complete high school, completed some college, or completed college or higher education versus completed high school), household income ($15 000-$24 999, $25 000-$49 999, or ≥$50 000 versus <$15 000), recruitment source (community health center versus general population), and body mass index (<20.0, 25.0-29.9, 30.0-34.9, 35.0-39.9, or ≥40.0 versus 20.0-24.9 kg/m 2 ). We also included adjustment for histories of hypertension and diabetes mellitus when evaluating allcause and CVD mortality, but little change was found in the smoking risk estimates, and these adjustments were not pursued further.
We computed age-adjusted rates of mortality among never smokers by race and sex to aid in comparison of absolute (rather than relative) differences in risk between menthol and nonmenthol smokers and blacks and whites. All statistical tests were 2 tailed with values of P<0.05 considered significant. Analyses were performed with SAS version 9.3 (SAS Institute Inc, Cary, NC).
Results
Men were more likely to have smoked than women (76% and 54% respectively; P<0.0001). Among current and former smokers, menthol cigarette smoking was much more prevalent among blacks than whites (84% versus 27%; P<0.0001). The median pack-years of cigarette smoking for current smokers of menthol and nonmenthol cigarettes were 14.5 pack-years (interquartile range, 7.6-24.0 pack-years) and 18.5 packyears (interquartile range, 10.2-31.5 pack-years), respectively, among blacks and 28.0 pack-years (interquartile range, 15.5-40.0 pack-years) and 31.0 pack-years (interquartile range, 18.5-45.0 pack-years) among whites. Menthol smokers reported smoking on average 1.1 and 1.7 fewer cigarettes per day than nonmenthol smokers among blacks and whites, respectively. Among blacks, menthol smokers tended to be almost 5 years younger on average than nonmenthol smokers, whereas the difference among whites was <1 year. Table 1 presents demographic and lifestyle variables by race and sex for the 65 600 SCCS participants included in the analyses.
Participants were followed up to ascertain vital status and cause of death for 8.1 years on average. Table 2 shows increased risks for CVD and heart disease mortality for all smoking categories compared with never smokers among both blacks and whites. In general, HRs were higher for white than black smokers and, regardless of race, for smokers of nonmenthol versus menthol cigarettes, with the differences most pronounced for current nonlight (≥10 cigarettes per day) smokers. Associations between smoking and stroke were generally weaker than those observed for CVD, with no clear differences between menthol and nonmenthol smokers. Table I in the online-only Data Supplement shows HRs and 95% CIs for cancer and chronic obstructive pulmonary disease mortality according to the detailed smoking categories shown in Table 2 and documents the much higher HRs for lung cancer and for all cancers combined (including lung cancer) than for CVD among all smoking categories. Table 3 shows the HRs and 95% CIs for all-cause, CVD, heart disease, and stroke mortality for menthol versus nonmenthol cigarette use among current smokers. In analyses of both races combined, there was no difference in risk between menthol and nonmenthol smokers for mortality from all causes (HR=0.93; 95% CI=0.86-1.01; P=0.10), CVD (HR=0.88; 95% CI=0.76-1.03; P=0.10), heart disease (HR=0.87; 95% CI=0.73-1.04; P=0.12), or stroke (HR=1.07; 95% CI=0.74-1.55; P=0.72). For comparison, the table also shows that menthol smokers experienced lower mortality risks from all cancers (HR=0.87; 95% CI=0.75-1.00) and lung cancer (HR=0.71; 95% CI=0.57-0.88) but not chronic obstructive pulmonary disease. Table II in the online-only Data Supplement presents demographic and lifestyle variables by race, sex, and cigarette type for the current smokers included in Table 3 .
Discussion
This study provides evidence that menthol cigarette smoking is not associated with higher CVD (and all-cause, heart disease, or stroke) mortality risk than nonmenthol cigarette smoking. We found no significant differences in risk of these diseases according to cigarette mentholation status, with HRs comparing all-cause and CVD mortality among menthol versus nonmenthol smokers slightly <1.0 rather than >1.0. Although risk of stroke was reported to be elevated among menthol versus nonmenthol cigarette smokers in a smaller cross-sectional study of current smokers from the National Health and Nutrition Examination Surveys (NHANES), 8 we found no association between menthol versus nonmenthol cigarette smoking and stroke mortality risk. The excess was limited to women and to nonblacks in the NHANES study, but we did not find significant increases in stroke mortality in either whites or women in the SCCS (the stroke HR among white women for menthol versus nonmenthol use among current smokers was 0.70, although the 95% CI was a wide 0.20-2.47). Lower intensity of smoking of menthol compared to nonmenthol cigarettes, which has been reported in several studies, [11] [12] [13] [14] [15] [16] was also observed in the SCCS. However, the slightly lower mortality risks among menthol smokers cannot be attributed to this difference because the analyses were stratified by smoking intensity or adjusted for pack-years of cigarette smoking. Quit rates are also unlikely to explain differences in mortality risks because previously published analyses in the SCCS reported equal odds of quitting among menthol and nonmenthol smokers. 17 Although cotinine levels, measured in a small subset of SCCS participants, tended to be somewhat lower for menthol than nonmenthol smokers, the adjusted differences were not significant. 18 For these analyses, we were unable to identify participants who may have smoked both menthol and nonmenthol cigarettes or to quantify the number of cigarettes smoked or length [19] [20] [21] and that most participants who switch end up switching back. 17 Therefore, participants who may have switched between cigarette types are likely to have had a negligible effect on our results. Misclassification of cigarette type is possible but is likely minimal because adults appear to report cigarette type more accurately than adolescents and the percentages of menthol cigarette smokers found in this cohort (84% among blacks and 27% among whites) are nearly equivalent to those found in the National Survey on Drug Use and Health. 3, 4 No information was available on the tar content of the cigarettes smoked, so we were unable to compare this factor between menthol and nonmenthol smokers.
The SCCS is a prospective cohort with large numbers of blacks and whites of similarly low socioeconomic status and is one of the nation's major investigations into disparities in major chronic diseases. Smoking data were recorded at baseline, and participants were followed up to ascertain mortality experience using linkages believed to capture nearly all deaths among Americans. 22, 23 Blacks account for approximately two thirds of the cohort, and a large majority of the black smokers reported menthol cigarette use, making this the largest cohort of menthol smokers currently being traced. The design of this study provided us with the opportunity to produce precise estimates of the hazards of menthol cigarettes while minimizing the effects of socioeconomic status and recall CI indicates confidence interval; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; and HR, hazard ratio. *Self-reported smoking status and type of cigarette usually smoked at entry into the cohort. †International Classification of Diseases, 10th Revision codes: CVD, I00 through I78; heart disease, I00 through I09, I11, I13, and I20 through I51; stroke, I60 through I69; cancer, C00 through C97; lung cancer, C34; cancer except lung cancer, C00 through C33 and C35 through C97; and nonasthma COPD, J40 through J44 and J47).
‡HRs and 95% CIs from Cox proportional hazards models adjusted for race (black, white), sex, enrollment source (community health centers, general population), education (<12 years, 12 years, some college, college or beyond), income (<$15 CI indicates confidence interval; CVD, cardiovascular disease; and HR, hazard ratio. *Smoking status, type of cigarette usually smoked, and average number of cigarettes smoked per day were self-reported at entry into the cohort. †HRs and 95% CIs from Cox proportional hazards models adjusted for race (black, white), sex, enrollment source (community health centers, general population), education (<12 years, 12 years, some college, college or beyond), income (<$15 000, $15 000-$24 999, $25 000-$49 999, ≥$50 000), and body mass index (<20.0, 20.0-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, ≥40.0 kg/m 2 ), with age used as the time scale. ‡Age-adjusted annual mortality rates per 1000 among never smokers were 14.36 for blacks and 12.96 for whites for all deaths, 5.33 for blacks and 4.87 for whites for CVD, 3.73 for blacks and 4.36 for whites for heart disease, and 1.14 for blacks and 0.42 for whites for stroke.
§International Classification of Diseases, 10th Revision codes I00 through I78. ¶International Classification of Diseases, 10th Revision codes I00 through I09, I11, I13, and I20 through I51. ║International Classification of Diseases, 10th Revision codes I60 through I69. #No white participants in this smoking category died of stroke. **Significant difference comparing nonmenthol and menthol cigarettes within a smoking status/cigarettes per day category. 
